HC Wainwright maintains Scribe Therapeutics $60 share price target
Scribe Therapeutics’ price target was maintained by HC Wainwright & Co. at $60.00 per share,
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.